Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Lembas

Clinicaltrial registered13 Nov 2026

Lembas

13 Nov 2026: Trial registered · Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
13 Nov 2026
Title
Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight
Conditions
Appetite and Hunger, Suppression, Satiety and Appetite, Weight Change, Gastrointestinal Symptoms
Phase
Not applicable
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United States
Country
United States
Reference
NCT07936838
Location
United States
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Lembas

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.